CVS Health Shares Are Trading Higher After Cowen Maintained Its Buy Rating and Raised Its Price Target From $73 to $80. Piper Sandler Also Maintained Its Overweight Rating, but Lowered Its Price Target From $72 to $64.
CVS Health Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains CVS Health(CVS.US) With Buy Rating, Cuts Target Price to $64
Piper Sandler Sticks to Their Buy Rating for CVS Health (CVS)
TD Cowen Maintains CVS Health(CVS.US) With Buy Rating, Raises Target Price to $80
CVS Health's Strategic Turnaround: Poised for Growth in Medicare Advantage and Market Share Gains by 2025